PKM2 has been found to enhance the chemoresistance ability of CRC cells [84], based on a study in which PKM2 levels were significantly higher in oxaliplatin-resistant CRC cells than oxaliplatin-sensitive cells [86]. Here, PKM is linked to colorectal carcinoma.